Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
insulin detemir (Levemir®)
Reference No. 1427
Publication date:
13/12/2012
Last review date:
30/11/2016
Appraisal information
insulin detemir (Levemir®) solution for injection
Company:
Novo Nordisk Ltd
BNF category:
Endocrine system
NMG meeting date:
09/10/2012
AWMSG meeting date:
14/11/2012
Submission Type:
Limited Submission
Status:
Recommended
Advice No:
3912
Ratification by Welsh Government:
11/12/2012
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Insulin detemir (Levemir®) is recommended as an option for use within NHS Wales for the treatment of diabetes mellitus in children aged 1–5 years.
Final Appraisal Recommendation (FAR)
Download
insulin detemir (Levemir) 1427 FAR
insulin detemir (Levemir) 1427 Review of existing advice
AWMSG Secretariat Appraisal Report (ASAR)
Download
insulin detemir (Levemir) 1427 ASAR
Clinical Expert (CE) Summary
Download
insulin detemir (Levemir) 1427 CE summary
